Stay updated with breaking news from Active Sites. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Algiax Pharmaceuticals, today provided an update on its ongoing Phase 2a study (NCT04429919) with lead candidate AP-325 in patients with chronic neuropathic pain.
Total quarterly revenues increased 15.5% year-over-year from Q3 '22 Subscription service revenues increased 24.6% year-over-year from Q3 '22 Annual Recurring Revenue grew to $128.3 million -...
In the dynamic imaging of interfacial electrochemistry, advancement has been made by the research group headed by Professor Xianwei Liu from the Department of Environmental Science and Engineering of the University of Science and Technology of China (USTC) of the Chinese Academy of Science (CAS).
09.08.2023 - PAR Technology Corporation (NYSE: PAR) (“PAR Technology” or the “Company”) today announced its financial results for the second quarter ended June 30, 2023. Summary of Fiscal 2023 Second Quarter Revenues were reported at $100.5 million for the three ...
Total quarterly revenues increased 18.2% year-over-year from Q2 '22 Annual Recurring Revenue grew to $122.5 million - a 24.3% increase from $98.6 million reported in Q2 '22 ...